Articles tagged with Metastasis
A new gene expression test distinguishes between metastasizing and non-metastasizing head and neck cancers with high accuracy. The test was validated in a large multi-center cohort, predicting the absence of metastasis in 89% of cases.
A newly discovered biological pathway transforms normal cells into aggressive tumors by regulating the epithelial-mesenchymal transition (EMT) process. This mechanism involves a specific molecular factor called hnRNP E1, which can be used as a diagnostic approach for cancer.
Research at University of California, San Diego School of Medicine identifies regulatory T cells as primary source of RANKL protein, accelerating breast cancer spread. Interfering with RANKL interaction with cancer cells may block tumor progression, offering potential target for drug therapy.
Researchers identified a new role for focal adhesion kinase in producing vascular leakiness in lung tissue, increasing expression of E-selectin and attracting cancer cells. Blocking FAK activity reduced both vascular permeability and metastatic cell adhesion.
Researchers found that photodynamic therapy can eliminate tumor-associated lymphatic vessels and in-transit tumor cells, reducing metastasis. This approach could be combined with existing surgical techniques to destroy lymphatic vessels draining from tumors.
A study found that removing only the first lymph node (sentinel lymph node dissection) did not impact overall survival for women with early-stage breast cancer. The use of this method resulted in fewer complications compared to more extensive axillary lymph node dissection.
Scientists at Georgia Institute of Technology have found a regulatory RNA called miR-429 that can induce metastatic cancer cells to convert back into less invasive forms. This discovery may allow physicians to treat ovarian cancer more effectively with traditional chemotherapy.
A team of researchers has identified a potential biomarker for predicting future metastasis in patients with the most common form of liver cancer. Quantification of the mRNA template for a truncated version of the protein carboxypeptidase E (CPE) was found to predict intrahepatic metastasis with high sensitivity and specificity.
A team of researchers has identified a potential biomarker for predicting future metastasis in patients with the most common form of liver cancer. They also explored a new gene therapy approach to treating the underlying cause of most forms of muscular dystrophy.
Researchers found that high levels of a particular protein in cancer cells can predict cancer spread with high accuracy. The protein, CPE-delta N, was measured in tumors and surrounding tissues from patients with liver and rare tumors, with results showing that it can accurately predict metastasis or recurrence.
Researchers at Virginia Tech have developed a new method to detect the ability of breast cancer cells to metastasize, using specific silicon microdevices. The technology has the potential to provide important diagnostic and prognostic markers unique to the tumor.
VIB-K.U. Leuven scientists have decoded a potential new anti-cancer mechanism by normalizing abnormal tumor blood vessels through HRG, which prevents metastasis and enhances chemotherapy efficiency. This mechanism offers alternative possibilities for cancer treatment.
A new study shows that protein HRG activates specific immune cells to inhibit tumor growth and metastasis. HRG enhances chemotherapy effects and transforms inflammatory cells from promoting to inhibiting tumor growth.
Researchers found that endothelin-A receptor antagonist drugs only reduce tumor growth at metastasis sites, not large tumors. These drugs block the action of protein ET-1, which stimulates cancer cell growth and spread.
A study found that high circulating tumor cells (CTCs) are an independent prognostic marker for poor overall survival in metastatic breast cancer patients undergoing first-line chemotherapy. Persistence of high CTC levels during therapy was also an early marker of poor outcome.
Denosumab was found to delay the time to first skeletal-related event by 18% and the time to first and subsequent event by 22%, while overall survival and disease progression were similar between groups. The treatment also showed a lower rate of jaw osteonecrosis compared to zoledronic acid.
Fox Chase researchers have discovered several tumor characteristics that increase the risk of brain metastases in breast cancer patients. These include high-grade tumors, negative progesterone receptor status, and inflammatory breast cancer. The study aims to identify women at risk for brain metastases, potentially leading to preventiv...
A study found that PET/CT scans can predict local recurrence in lung cancer patients treated with radiofrequency ablation by analyzing lesion size, tumor type, and glucose metabolic activity. This non-invasive tool may help improve diagnosis and treatment of lung cancer.
Researchers found decreased alpha-2 integrin expression predicts tumor dissemination and lower survival rates in breast and prostate cancer. Alpha-2 integrin suppression of metastasis was confirmed using a mouse model and human microarray databases.
A study found that decreased physician reimbursement for hormone therapy reduced its use in low-risk prostate cancer cases by 40%. However, AST usage remained unchanged in patients with metastatic disease. The decrease is attributed to the real effect of reimbursement change.
A new study finds that a less invasive method for determining lung cancer stage improves detection of metastases and reduces surgical procedures. The method, which combines endosonography and ultrasound, was more effective than traditional surgical staging in identifying patients who needed further treatment.
A recent study published in Cancer found that clinical stage does not predict recurrence risk for patients with localized prostate cancer after having their prostate removed. Despite frequent errors in assigning stage, there was no association between clinical stage and prostate cancer recurrence.
Researchers at Washington University School of Medicine identified a gene linked to eye melanoma metastasis. BAP1 mutations were found in 84% of metastatic tumors but rare in non-metastatic ones. The discovery may lead to more effective treatments and insights into cancer cell evolution.
A recent IRCM breakthrough reveals a novel molecular mechanism that regulates cell motility, a key factor in tumour spread. The study identifies the ELMO protein's regulatory feature as critical in preventing uncontrolled cell migration.
Researchers at Mayo Clinic discovered that epithelial cadherin (E-cadherin), a protein believed to be a beneficial tumor suppressor, can act as an oncogene in some lethal brain tumors. This finding suggests E-cadherin expression may promote tumor growth and migration, challenging current understanding of its role in cancer progression.
A new study from Johns Hopkins Medicine finds that pancreatic cancers develop and spread much more slowly than previously thought. The research suggests that there is a potentially broad window for diagnosis and prevention of the disease, with an average progression time of 11.7 years.
Researchers uncovered unique genomic instability in pancreatic cancer, which drives tumor adaptation and spread. This study highlights the need for improved early diagnosis methods and targeted treatments.
Researchers at MD Anderson Cancer Center identified a key signaling pathway that promotes osteosarcoma metastasis when blocked in mice. The study found significant decreases in lung metastases by targeting the Notch pathway and Hes1 gene.
Routine prostate cancer screening significantly reduces the risk of metastatic disease within 10 years after treatment. Men diagnosed post-screening had a lower risk of spreading cancer compared to those treated prior to widespread screening.
A large study found that men with localized prostate cancer who take aspirin with radiation therapy or surgery have a lower risk of dying from the disease. The use of anticoagulants reduced the risk of death by 6 percentage points, from 10% to 4%, at 10 years.
Researchers at Penn State College of Medicine have identified a potential new treatment approach targeting the protein c-Met in patients with metastatic liver cancer. By analyzing data from 1,051 patients and six published manuscripts, they found that c-Met activation is strongly associated with poor prognosis and aggressive features. ...
Researchers at UT MD Anderson Cancer Center found that TAp63, a tumor-suppressing protein, blocks cancer spread by activating Dicer and miR-130b. This discovery has far-reaching implications for understanding cancer development and metastasis.
A Phase-II trial investigating pazopanib for relapsed/refractory urothelial cancer has generated promising results, with four patients experiencing tumor shrinkage and twelve seeing their metastases die due to 'necrotic evolution'. Researchers are eager to translate this activity into a survival advantage.
Researchers reported that adding cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer did not improve response rates, progression-free survival, or overall survival. The NORDIC VII study included 566 patients and found no statistically significant differences between the treatment groups.
Researchers have found that cancer cells are accompanied by growth-enabling stromal cells when they travel to new sites in the body. This discovery challenges current understanding of metastasis and has implications for effective treatments.
A new meta-analysis shows that continuing chemotherapy after bringing cancer under control can increase survival time and reduce disease progression in metastatic breast cancer patients. The analysis found a 34% reduction in disease progression and a 9% reduction in death rates for patients who received longer chemotherapy durations.
A new melanoma treatment has shown a robust activity in shrinking brain metastases in patients with advanced disease. The drug, GSK2118436, targets the BRAF protein mutation common in human melanomas and has been found to control and reduce brain tumor size in nearly all patients.
The final phase-II results show that iniparib plus chemotherapy significantly improves overall survival from 7.7 to 12.3 months, offering a promising new treatment option for metastatic triple-negative breast cancer patients. Over half of patients experience clinical benefit, and there is little increase in adverse events.
A new type of cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease. The study demonstrated that T-DM1 has good anti-tumor activity and much lower toxicity compared to the older standard.
The $1.5 million grant will fund Ben Major's work to identify functional human genes contributing to specific cellular processes, such as cancer growth and migration. The goal is to develop a low-cost approach to determine gene function in the human genome.
A recent clinical study has shown that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases. The vaccine was found to be effective in one particular patient who remained in complete remission for over two years, more than four years after her initial diagnosis.
Researchers have identified LIMK as a crucial regulator of actin cytoskeleton dynamics in cancer metastasis. Inhibiting LIMK function blocks collective invasion of tumor cells, preventing metastasis in breast and squamous carcinoma cells.
Research found that chronic stress increases cancer spread by 30-fold in stressed mice compared to unstressed controls. Stress alters the biology of immune cells, promoting metastasis to distant organs. Beta blockers blocked this effect, suggesting potential prevention strategies.
CD82 and CD9 proteins are found to suppress tumor metastasis by releasing beta-catenin in exosomes, thereby inhibiting Wnt signaling. This mechanism may be compromised in certain cancers, where Wnt signaling is hyperactive.
A study by Heike Allgayer's team found that micro-RNA miR-200c inhibits the motility and invasive capacity of non-small cell lung cancer cells. Higher miR-200c levels were associated with increased tissue-anchoring molecules and lower metastasis rates.
Researchers have developed a new drug that targets peripheral CB1 cannabinoid receptors to improve cardiometabolic risk in mouse models of obesity. The drug inhibits the same protein as rimonabant, but without neurological side effects. This approach may reduce health risks associated with obesity and type 2 diabetes.
Researchers from A*STAR made three groundbreaking discoveries in fight against cancer: a mechanism to prevent metastasis, biomarkers for breast cancer, and improved detection of cervical cancer. Their work sheds light on key areas of cancer research, offering new strategies to combat this devastating disease.
A recent study uses genomic analysis to understand complex cellular signals driving lung cancer's deadly spread. The research identifies specific molecules linked to non-small cell lung cancer's (NSCLC) invasive and metastatic processes, providing a basis for effective therapies.
UAB researchers are investigating the role of inactivated DNA left behind after breast-cancer treatment. They aim to understand how this altered DNA activates cancer's deadly spread, a process called metastasis. The study could lead to improved prevention and treatment for millions of cancer patients.
A phase III clinical trial found that ipilimumab, a monoclonal antibody, significantly extended the lives of patients with metastatic melanoma. The therapy showed a 67% increase in survival time compared to those receiving gp100 alone, demonstrating its promise as an alternative treatment for cancer patients.
Researchers found that cancer cells lacking COMMD1 are more invasive and likely to metastasize, suggesting a possible drug target. Enhanced COMMD1 levels in mouse melanoma cells reduced metastatic lung tumors.
Only 5% of cancer research funds are spent on investigating metastases, yet it kills 90% of all cancer patients. The European CanCer Organisation highlights this discrepancy in funding and calls for increased emphasis on tackling metastases.
A new Mayo Clinic study found that complete removal of all tumors that spread can significantly improve prognosis for kidney cancer patients. Patients who underwent complete tumor removal had an average cancer-specific survival rate of 5 years, compared to just 1 year for those without metastatic tumors removed.
Scientists identified a novel enzyme, PEAK1, that regulates cell proliferation, shape and migration. The discovery may provide a new target for future anti-cancer therapies.
Researchers at Mayo Clinic have found a new aggressive treatment approach for anaplastic thyroid carcinoma to be highly effective, resulting in 70% one-year survival rate. The treatment combines surgery, intensity modulated radiation therapy, and chemotherapy, and is being tested in a nationwide clinical trial.
A recent study by S. Eggener et al. discusses the significance and impact of focal therapy for low-risk prostate cancer patients, highlighting its potential as an alternative to whole-gland treatment. The study reviews patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for focal therapy.
Researchers at Beth Israel Deaconess Medical Center have identified palladin as a critical regulator of cell motility and migration in breast cancer. By inhibiting these processes, palladin helps suppress breast cancer invasion and metastasis.
Researchers found that PDE5 inhibitors increase blood-brain barrier permeability to Herceptin, boosting effectiveness against lung and breast cancer brain metastases. The combination of vardenafil plus Herceptin improved survival by 20% in mouse models.
A recent study presented at the ARRS Annual Meeting found that whole body MRI is highly accurate in detecting breast cancer metastases. The test identified bone metastases in 47 out of 99 patients with known breast cancer, while a chest X-ray only detected them in 24 patients.
A new study found that the number of circulating tumor cells in a patient's blood directly correlates with their survival time in metastatic breast cancer. The research suggests that monitoring these cells could improve personalized therapy for patients.